Early clinical trials evaluating PI3K inhibitors have shown disappointing results, but further evaluation with more potent agents and careful patient selection might lead to development of effective PI3K inhibitors in HNSCC. This evidence concerns the gene PIK3CA and head and neck squamous cell carcinoma.